Lactobacillus reuteri DSM 17938 alleviates d-galactosamine-induced liver failure in rats.
Acetaminophen
Animals
Chemical and Drug Induced Liver Injury
/ blood
Cytokines
/ blood
Disease Models, Animal
Dysbiosis
Galactosamine
Gastrointestinal Microbiome
/ drug effects
Ileum
/ metabolism
Inflammation Mediators
/ blood
Limosilactobacillus reuteri
/ physiology
Liver
/ metabolism
Liver Failure
/ blood
Male
Metabolome
Peroxisome Proliferator-Activated Receptors
/ genetics
Probiotics
Rats, Sprague-Dawley
Signal Transduction
Transcriptome
Gut microbiota
Lactobacillus reuteri DSM 17938
Liver failure
Metabolome
Transcriptome
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
01
09
2020
revised:
05
11
2020
accepted:
08
11
2020
pubmed:
18
11
2020
medline:
25
2
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
Liver failure is a serious hepatic dysfunction with high mortality. This work aimed to investigate the effect of a famous probiotic and drug, Lactobacillus reuteri DSM 17938, on liver failure in rats. Sprague-Dawley rats were gavaged with 3 × 10
Identifiants
pubmed: 33202285
pii: S0753-3322(20)31192-6
doi: 10.1016/j.biopha.2020.111000
pii:
doi:
Substances chimiques
Cytokines
0
Inflammation Mediators
0
Peroxisome Proliferator-Activated Receptors
0
Acetaminophen
362O9ITL9D
Galactosamine
7535-00-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111000Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.